Which US stock sectors look strongest now? 4 areas with real catalysts

The S&P 500 is still close to record territory, but sector performance has become increasingly uneven.

Energy is up about 54% in 2026, technology around 33% and healthcare roughly 14%, while financials have gained less than 1%. The broader S&P 500 is up about 14%.

Those gaps show why simply buying the index is becoming a less complete way to read the market. Technology still has the strongest earnings engine, energy has benefited from high oil prices, healthcare is attracting fresh interest as investors look beyond AI, while financials are producing mixed but potentially useful signals about rates and credit.

For Australian traders, the different drivers across these sectors create more targeted opportunities than simply taking a view on the S&P 500. CFDs can provide long or short exposure to individual US shares as earnings, rates and commodity prices push sectors in different directions.

Technology remains one of the strongest-performing sectors of 2026, up roughly 33% despite a recent sell-off in AI-linked stocks. The earnings case is still strong. TSMC has just reported its sixth consecutive quarter of record profit, with quarterly net income rising 69% and 2026 revenue now expected to grow about 44%. That provides fresh evidence that demand for advanced AI chips remains exceptionally strong.

Nvidia, AMD, Broadcom and Microsoft are all benefiting from the same spending cycle across accelerators, networking, cloud infrastructure and data centres. The challenge is that investors have already priced in years of rapid growth.

The semiconductor sectorhas recently suffered a sharp pullback as concerns rise over the amount of debt being used to finance AI infrastructure. Even strong earnings are no longer enough if forward guidance fails to clear increasingly high expectations.

Technology therefore still has one of the strongest fundamental cases, but it also carries the greatest valuation pressure of the four sectors. Earnings need to keep growing fast enough to offset higher yields and justify prices that have already run far ahead of the broader market.

Healthcare has returned about 14% this year and has recently attracted stronger buying as technology volatility increases.

The sector offers a very different source of growth. Eli Lilly continues expanding its obesity and diabetes pipeline, while UnitedHealth has raised its full-year profit outlook after stronger quarterly earnings. Drug development, medical technology and healthcare services can all produce growth without depending on AI infrastructure spending or falling bond yields.

Recent dealmaking has added another catalyst. New partnerships and acquisitions across obesity treatments and biotechnology show that large healthcare companies are still willing to spend heavily to secure future growth.

Healthcare also benefits from more defensive demand. Patients still require medicines, insurance and treatment even when economic conditions weaken, which can make the sector more attractive when investors become less comfortable with expensive technology stocks.

The main risks come from drug failures, pricing pressure and medical-cost inflation, but the combination of stronger earnings and lower dependence on the economic cycle gives healthcare a useful role alongside more volatile growth sectors.

Financials have barely moved in 2026, with the main sector ETF up less than 1% for the year.

That weak performance reflects a much more mixed earnings picture.

Goldman Sachs has benefited from surging equity trading, while JPMorgan has also reported strong markets revenue. Citigroup’s restructuring is beginning to improve returns, but traditional banking faces more pressure from deposit costs, slower lending growth and higher credit provisions.

Higher rates can still support net interest income, but only if loan yields rise faster than the cost of deposits and wholesale funding. Recent bank earnings have shown that relationship is becoming less favourable for some lenders.

For investors, financials currently look less like a broad sector trade and more like a stock-selection story. Goldman offers greater exposure to active markets and dealmaking, while JPMorgan combines trading strength with a huge consumer franchise. Wells Fargo and other traditional lenders remain more sensitive to credit growth and funding costs.

The next catalyst will be whether stronger trading and investment banking can offset softer lending and rising provisions as high rates persist.

Energy has delivered the biggest gains of the major US sectors, rising roughly 54% this year. Oil prices remain the main driver. Brent has stayed above $100 as geopolitical tensions and supply disruptions keep global markets tight, supporting cash flow across producers such as ExxonMobil and Chevron.

Refining margins have also strengthened, giving integrated oil companies another source of earnings beyond crude production.

The sector now faces a different question from technology. Valuations are not being driven by expectations of explosive future growth; they are being supported by current commodity prices and cash generation.

That makes energy particularly sensitive to any easing in geopolitical risk or improvement in supply. A sustained fall in crude would quickly weaken the earnings tailwind, while prices above $100 continue to support producers and refiners.

High oil also creates a broader market risk. Expensive energy feeds inflation and increases pressure on the Federal Reserve to keep rates high, meaning the same conditions helping Exxon and Chevron can hurt technology, consumer, and rate-sensitive stocks.

The four sectors offer very different combinations of momentum and catalysts. 

Energy has produced the strongest returns and still benefits from high oil prices, but much of the move has already occurred, and the trade remains heavily dependent on crude.

Technology continues to deliver the fastest earnings growth, although valuations and AI financing concerns have raised the hurdle for further gains.

Healthcare has lagged those two leaders but is building momentum through stronger earnings, obesity treatments and renewed dealmaking, while also offering more defensive characteristics.

Financials have been the weakest of the four on a YTD basis, but the sector contains significant divergence between trading-heavy banks and traditional lenders.

That leaves investors choosing between very different sources of potential upside rather than one dominant market theme.

Technology earnings remain the biggest near-term test. Nvidia, AMD, Microsoft and other AI leaders need to show that spending and profit growth remain strong enough to justify current valuations.

Healthcare investors will be watching obesity-drug pipelines, insurer earnings and further deal activity, while financials depend on whether strong trading revenue can offset slower lending and higher credit provisions.

For energy, crude prices remain the clearest signal. Any easing in supply risks could quickly reduce the sector’s strongest current catalyst.

Trading US sectors with Mitrade

The widening gap between US sectors creates different trading setups across technology, healthcare, financials and energy.

Through Mitrade, eligible Australian clients can use CFDs to take long positions when expecting individual US shares to rise or short positions when expecting further weakness. That allows separate views across companies such as Nvidia, Eli Lilly, JPMorgan and ExxonMobil rather than relying only on the direction of the S&P 500.

Stop-loss and take-profit orders can define exit levels, while pending orders allow positions to open only when a selected price is reached. Accounts can be funded in AUD, and a demo account is available for testing strategies without committing real capital.

Mitrade is regulated in Australia by ASIC. CFDs are leveraged products, so both potential gains and losses can be magnified.

Start trading US shares in three simple steps

You might be interested in…